Pregabalin Capsule
Product Images NDC 80425-0123

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The y-axis represents percent of patients improved, and the x-axis represents percent improvement in pain.*

FDA Label Image

Fig 10

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without loss to follow-up (LTR) over 180 days between Pregabalin and Placebo groups. The x-axis represents days, and the y-axis represents the estimated percentage of subjects without LTR, with Pregabalin showing higher retention compared to Placebo.*

FDA Label Image

Fig 11

A line chart comparing percent improvement from baseline to Week 12 between Pregabalin and Placebo groups. The x-axis shows percent improvement in Brief Overall Cognitive Function (BOCF) scores from 0 to 100, and the y-axis displays the percent of subjects improved from 0 to 100. Two lines represent Pregabalin and Placebo outcomes, with Pregabalin generally showing higher percent improvement.*

FDA Label Image

Fig 12

A line graph comparing the percent of subjects improved from baseline to Week 16 using the BOCF method. The x-axis shows percent improvement from greater than 0 to 100 percent, and the y-axis shows the percent of subjects improved from 0 to 100. Two lines represent Pregabalin and Placebo, with Pregabalin consistently showing a higher percentage of improvement.*

FDA Label Image

Fig 2

A chart depicting the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares two groups: patients treated with Pregabalin 100 mg taken three times a day and patients given a placebo, showing differences in pain improvement over various thresholds.*

FDA Label Image

Fig 3

A line graph depicting percent improvement in pain from baseline over time, comparing Pregabalin at 75 mg, 150 mg, and 300 mg doses taken twice a day, versus placebo. The y-axis represents percent of patients improved, and the x-axis shows time points. The data illustrate the relative efficacy of the different Pregabalin doses compared to placebo.*

FDA Label Image

Fig 4

A line graph comparing the percent improvement in pain from baseline to the percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph shows three distinct plotted lines representing each group’s response over a pain improvement range from 0 to 100 percent.*

FDA Label Image

Fig 5

A graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with lines differentiating each treatment effect over the range of improvement percentages.*

FDA Label Image

Fig 6

A bar graph depicting responder rates (%) in two studies labeled E1 and E3 for different doses of Pregabalin taken orally. The graph compares placebo and increasing doses from 50 mg/day to 600 mg/day, with dosing frequencies BID and TID indicated. The chart highlights statistically significant responder rates versus placebo at higher doses, with sample sizes noted below each bar.*

FDA Label Image

Fig 7

A line chart depicting seizure reduction as median percentage change from baseline across different pregabalin doses (0, 50, 150, 300, and 600 mg/day) from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID). The chart includes statistical significance (p-values) for observed reductions, indicating dose-dependent efficacy compared to placebo.*

FDA Label Image

Fig 9

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 600 mg daily doses compared to placebo. The vertical axis represents the percent of patients improved, while the horizontal axis shows the percent improvement in pain, ranging from 0 to 100 percent.*

FDA Label Image

Formula

An illustration showing the formula for calculating creatinine clearance (CLCr), which includes patient age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Pregabalin 100mg Cap Qty 90 80425 0123

Label for Pregabalin 100 mg capsules, product NDC 80425-0123, manufactured by Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes a barcode, lot number PRE100722, and storage instructions to keep at 20-25°C (68-77°F). It notes the product is for prescription use only and compares to LYRICA.*

FDA Label Image

Structure

Chemical structure diagram of Pregabalin showing its molecular configuration with carboxyl (CO2H) and amino (NH2) functional groups, consistent with the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.